The HUNT study: Association of comorbidity clusters with long-term survival and incidence of exacerbation in a population-based Norwegian COPD cohort
- PMID: 35144315
- DOI: 10.1111/resp.14222
The HUNT study: Association of comorbidity clusters with long-term survival and incidence of exacerbation in a population-based Norwegian COPD cohort
Abstract
Background and objective: Chronic obstructive pulmonary disease (COPD) is a heterogeneous disease often viewed as part of a multimorbidity complex. There is a need for better phenotyping of the disease, characterization of its interplay with other comorbidities and its association with long-term outcomes. This study aims to examine how clusters of comorbidities are associated with severe exacerbations and mortality in COPD.
Methods: Participants with potential COPD were recruited from the second (1995-1997) and third (2006-2008) survey of the HUNT Study and followed up until April 2020. Ten objectively identified comorbidities were clustered using self-organizing maps. Severe COPD exacerbations requiring hospitalization were assessed using hospital data. All-cause mortality was collected from national registries. Multivariable Cox regression was used to calculate hazard ratios (HRs) with 95% CIs for the association between comorbidity clusters and all-cause mortality. Poisson regression was used to calculate incidence rate ratios (IRRs) with 95% CI for the cumulative number of severe exacerbations for each cluster.
Results: Five distinct clusters were identified, including 'less comorbidity', 'psychological', 'cardiovascular', 'metabolic' and 'cachectic' clusters. Using the less comorbidity cluster as reference, the psychological and cachectic clusters were associated with all-cause mortality (HR 1.23 [1.04-1.45] and HR 1.83 [1.52-2.20], adjusted for age and sex). The same clusters also had increased risk of exacerbations (unadjusted IRR of 1.24 [95% CI 1.04-1.48] and 1.50 [95% CI 1.23-1.83], respectively).
Conclusion: During 25 years of follow-up, individuals in the psychological and cachectic clusters had increased mortality. Furthermore, these clusters were associated with increased risk of severe COPD exacerbations.
Keywords: COPD exacerbation; HUNT study; chronic obstructive pulmonary disease; clinical epidemiology; comorbidity cluster.
© 2022 Asian Pacific Society of Respirology.
Comment in
-
Severe exacerbations and mortality in COPD: Importance of both body and mind.Respirology. 2022 Apr;27(4):256-257. doi: 10.1111/resp.14235. Epub 2022 Mar 6. Respirology. 2022. PMID: 35253316 No abstract available.
Similar articles
-
In-hospital and one-year mortality and their predictors in patients hospitalized for first-ever chronic obstructive pulmonary disease exacerbations: a nationwide population-based study.PLoS One. 2014 Dec 9;9(12):e114866. doi: 10.1371/journal.pone.0114866. eCollection 2014. PLoS One. 2014. PMID: 25490399 Free PMC article.
-
Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease.Am J Respir Crit Care Med. 2013 Apr 1;187(7):728-35. doi: 10.1164/rccm.201209-1665OC. Am J Respir Crit Care Med. 2013. PMID: 23392440
-
Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality.Thorax. 2012 Nov;67(11):957-63. doi: 10.1136/thoraxjnl-2011-201518. Epub 2012 Jun 8. Thorax. 2012. PMID: 22684094 Free PMC article.
-
Cardiovascular events after exacerbations of chronic obstructive pulmonary disease: Results from the EXAcerbations of COPD and their OutcomeS in CardioVascular diseases study in Italy.Eur J Intern Med. 2024 Sep;127:97-104. doi: 10.1016/j.ejim.2024.04.021. Epub 2024 May 9. Eur J Intern Med. 2024. PMID: 38729787
-
Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).Cochrane Database Syst Rev. 2017 Jun 20;6(6):CD011897. doi: 10.1002/14651858.CD011897.pub2. Cochrane Database Syst Rev. 2017. PMID: 28631387 Free PMC article. Review.
Cited by
-
The AGE-RAGE Axis and the Pathophysiology of Multimorbidity in COPD.J Clin Med. 2023 May 9;12(10):3366. doi: 10.3390/jcm12103366. J Clin Med. 2023. PMID: 37240472 Free PMC article. Review.
-
Rational use of inhaled corticosteroids for the treatment of COPD.NPJ Prim Care Respir Med. 2023 Jul 24;33(1):27. doi: 10.1038/s41533-023-00347-6. NPJ Prim Care Respir Med. 2023. PMID: 37488104 Free PMC article. Review.
-
ERS International Congress 2022: highlights from the Respiratory Intensive Care Assembly.ERJ Open Res. 2023 May 22;9(3):00532-2022. doi: 10.1183/23120541.00532-2022. eCollection 2023 May. ERJ Open Res. 2023. PMID: 37228293 Free PMC article. Review.
References
REFERENCES
-
- Vogelmeier C, Agusti A, Anzueto A, et al. Global initiative for chronic obstructive lung disease; 2020. Available from: https://goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-0.... Accessed February 02, 2022.
-
- Mannino DM, Higuchi K, Yu TC, Zhou H, Li Y, Tian H, et al. Economic burden of COPD in the presence of comorbidities. Chest. 2015;148(1):138-50.
-
- Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(2):155-61.
-
- Corlateanu A, Covantev S, Mathioudakis AG, Botnaru V, Siafakas N. Prevalence and burden of comorbidities in chronic obstructive pulmonary disease. Respir Investig. 2016;54(6):387-96.
-
- Yin HL, Yin SQ, Lin QY, Xu Y, Xu HW, Liu T. Prevalence of comorbidities in chronic obstructive pulmonary disease patients: a meta-analysis. Medicine (Baltimore). 2017;96(19):e6836.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous